Biotech
Update
Biotech
Gene editing, mRNA, and pharma leaders. TMO RSI 25↓ entry. CRSP watching $45.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟢 RELATIVE STRENGTH - XBI +4.3% 30D while tech crashes |
| Key insight | TMO RSI 25↓ = life sciences tools entry. MRNA +32.9% recovery. |
| Position update | CRSP at $50.17 (-2.2% from entry), watching $45 support |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| ✅ STRONG BUY | TMO | RSI 25↓, life sciences tools leader |
| 📈 HOLD | CRSP | Existing position, watch $45 support |
| 🔍 WATCH | LLY, VRTX | Quality but not cheap |
| 🔍 RESEARCH | MRNA, NTLA | Recovery plays |
Data (Validated 2026-02-04)
| Stock | Price | 7D | 30D | 3M | 52wkHi | RSI | Status | Action |
|---|---|---|---|---|---|---|---|---|
| LLY | $1107.12 | -1.3% | +6.3% | +19.8% | -2.4% | 55 | 🟢 Near highs | 🔍 Wait pullback |
| TMO | $565.22 | -7.5% | -7.5% | -0.4% | -12.2% | 25↓ | 🟢 OVERSOLD | ✅ Buy |
| MRNA | $42.77 | -4.2% | +32.9% | +81.5% | -22.5% | 54 | 🟢 Recovery | 📈 Watch |
| CRSP | $50.17 | -2.8% | -9.0% | -12.0% | -36.1% | 38 | 🟡 Holding | 📈 Hold/Add $45 |
| NTLA | $12.36 | -6.3% | +31.9% | -8.9% | -56.3% | 52 | 🟡 Volatile | 🔍 Research |
| VRTX | $470.52 | -1.9% | +4.8% | +12.8% | -9.5% | 64 | 🟢 Strong | 🔍 Quality hold |
Key Positions
CRSP - CRISPR Therapeutics (Existing Position)
Thesis: First CRISPR drug (Casgevy) approved. Gene editing pioneer.
| Metric | Value |
|---|---|
| Entry | $51.31 |
| Current | $50.17 |
| Return | -2.2% |
| RSI | 38 |
| Entry zone | <$50 |
Status: Below entry but not by much. Watching for Casgevy commercial data.
Action: 📈 HOLD. Consider adding at $45 zone.
TMO - Thermo Fisher (Entry Zone)
Thesis: Life sciences tools monopoly. Every lab needs TMO equipment.
| Metric | Value |
|---|---|
| Current | $565.22 |
| 7D | -7.5% |
| RSI | 25↓ (Oversold) |
| 52wk High | -12.2% |
Analysis:
- RSI 25 = oversold for a quality compounder
- Life sciences tools = picks and shovels for biotech
- Defensive in biotech selloffs (equipment vs drugs)
Action: ✅ STRONG BUY at current levels
Entry Zones Status
| Stock | Entry Zone | Current | Status |
|---|---|---|---|
| TMO | <$600 | $565.22 | ✅ IN ZONE (RSI 25) |
| CRSP | <$50 | $50.17 | ⚠️ Just above zone |
| LLY | <$1000 | $1107.12 | 🔍 Not yet |
Next Actions
- Consider TMO position at RSI 25
- Watch CRSP for $45 add zone
- Monitor Casgevy commercial updates
- Research MRNA pipeline beyond COVID
Commands
cd stonks
the desk's own tooling
the desk's own tooling
the desk's own tooling
the desk's own tooling
Related
10 eventsNo direct external sources are attached to this read.